Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue 4, 2013, Pages 230-237

  Abidi, Afroz ^a  

^a SUBHARTI MEDICAL COLLEGE   (India)

Author keywords

Cabazitaxel; castration resistant prostate cancer; tropic trial

Indexed keywords

ABARELIX; ABIRATERONE; BICALUTAMIDE; BUSERELIN; CABAZITAXEL; CORTICOSTEROID; CYPROTERONE ACETATE; DEGARELIX; DIETHYLSTILBESTROL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; FINASTERIDE; FLUTAMIDE; GOSERELIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NILUTAMIDE; PACLITAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; TRIPTORELIN; UNINDEXED DRUG;

ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BINDING AFFINITY; BRONCHOSPASM; CARDIOTOXICITY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONSERVATIVE TREATMENT; DEHYDRATION; DIARRHEA; DOWN REGULATION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; EMBRYOTOXICITY; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FETUS DISEASE; FLUID RETENTION; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MINIMALLY INVASIVE PROCEDURE; MITOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; OBSTRUCTIVE UROPATHY; ORCHIECTOMY; PARESTHESIA; PELVIS LYMPHADENECTOMY; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; TENDON REFLEX; VIBRATION DISEASE; WATCHFUL WAITING;

EID: 84886533982     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.119704     Document Type: Review

References (30)

1. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology 2005;66 (5 Suppl):83-94.
2. Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, et al. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007;83:3-10.
3. Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, et al. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37:2-13.
4. Anderson J. The role of antiandrogenmonotherapy in the treatment of prostate cancer. BJU Int 2003;91:455-61.
5. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al.A phase 3, multicentre, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670-4.
6. Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008;5:506-7.
7. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: Arandomised open-label trial. Lancet 2010;376:1147-54.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. NEngl J Med 2010;363:411-22.
10. Ang JE, Olmos D, Bono JS. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;10:671-5.
11. Bouchet BP, Galmarini CM. Cabazitaxel. A new taxane with favorable properties. Drugs Today (Barc) 2010;46:735-42.
12. Jevtana (cabazitaxel) injection prescribing information. Bridgewater, NJ: Sanofi-aventis US; June; 2010.
13. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-8.
14. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30.
15. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010;5:395-402.
16. Bissery MC, Bouchard H, Riou J, Vrignaud P, Combeau C, Bourzat JD. Preclinical evaluation of TXD258, a new taxoid. Proceedings of the American Association for Cancer Research 2000:41. Cancer Research, Incorporated, and American Association for Cancer Research, Incorporated, 2000. Abstract 1364.
17. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery MC. In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proceedings of the American Association for Cancer Research 2000:41. Cancer Research, Incorporated, and American Association for Cancer Research, Incorporated, 2000. Abstract 1365.
18. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-81.
19. Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-52.
20. Heck MM, Höppner M, Horn T, Thalgott M, Gschwend JE, Retz M. Compassionate use of abiraterone and cabazitaxel: First experiences in docetaxel-pretreated castration-resistant prostate cancer patients. Urologe A 2012;51:390-7.
21. Gonçalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001;98:11737-42.
22. Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform 2007;3:159-81.
23. Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 2010;70:9253-64.
24. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008;15:841-9.
25. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003;89:968-70.
26. Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011;17:3892-902.
27. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, et al. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials. Ann Oncol 2010;21:312-8.
28. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
29. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375:1437-46.
30. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5.